Story perspectives

Novo Nordisk Partners With Anthropic to Accelerate AI Drug Discovery

By Drooid · Sep 17, 2026, 2:14 AM UTC · How we work

Summary

Story summary

Novo Nordisk announced a partnership with Anthropic to accelerate drug discovery using AI.
The firms will test Anthropic’s Claude Science platform in selected R&D workflows.
CEO Mike Doustdar said the deal will help Novo become the world’s most AI-driven healthcare company.
The agreement includes data-governance and human-oversight frameworks to ensure responsible AI use.
Pre-market trading showed Novo’s stock rose over 1% after the announcement.

History

Historical Context

In January 2014 IBM launched the Watson Group with a $1 billion investment, quickly partnering with hospitals such as the Cleveland Clinic and Memorial Sloan-Kettering to test AI-driven clinical decision support. Although early pilots showed faster data analysis, the division struggled and was sold to Francisco Partners in 2022. This history underpins today’s 2024 pharma-AI collaborations.

1 of 2

Story summary

Novo Nordisk announced a partnership with Anthropic to accelerate drug discovery using AI.
The firms will test Anthropic’s Claude Science platform in selected R&D workflows.
CEO Mike Doustdar said the deal will help Novo become the world’s most AI-driven healthcare company.
The agreement includes data-governance and human-oversight frameworks to ensure responsible AI use.
Pre-market trading showed Novo’s stock rose over 1% after the announcement.

1 / 2